Second Sight Medical Pro... Stock Price

-0.62 (-7.56%)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Second Sight Medical Products Inc EYES NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.62 -7.56% 7.58 08:12:36
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
7.57 7.65 0.08 1 -
Trades Volume Avg Volume 52 Week Range
404 45,803 2,148,330 0.6906 - 20.00
Last Trade Time Type Quantity Stock Price Currency
08:12:36 2 $ 7.65 USD

Second Sight Medical Pro... Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 175.96M 23.21M 12.69M $ 3.38M $ - -18.30 -0.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Second Sight Medical Pro... News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EYES Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.3110.387.958.736,317,035-0.73-8.78%
1 Month14.1415.757.249.447,079,386-6.56-46.39%
3 Months1.8720.001.408.9326,020,0505.71305.35%
6 Months0.8820.000.728.2713,731,2426.70761.36%
1 Year1.8920.000.69067.917,029,9385.69301.06%
3 Years1.8020.000.63517.442,548,3635.78321.11%
5 Years5.1820.000.63516.841,733,0652.4046.33%

Second Sight Medical Pro... Description

Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices, to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, France and Germany, of which key revenue is derived from the United States.

Your Recent History
Second Sig..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.